S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
MarketBeat Week in Review – 9/18 - 9/22
The federal government is headed into a shutdown. What does it mean, who's hit and what's next?
New AI Stock Payouts (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Auto workers still have room to expand their strike against car makers. But they also face risks
New AI Stock Payouts (Ad)
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
MarketBeat Week in Review – 9/18 - 9/22
The federal government is headed into a shutdown. What does it mean, who's hit and what's next?
New AI Stock Payouts (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Auto workers still have room to expand their strike against car makers. But they also face risks
New AI Stock Payouts (Ad)
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
MarketBeat Week in Review – 9/18 - 9/22
The federal government is headed into a shutdown. What does it mean, who's hit and what's next?
New AI Stock Payouts (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Auto workers still have room to expand their strike against car makers. But they also face risks
New AI Stock Payouts (Ad)
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
MarketBeat Week in Review – 9/18 - 9/22
The federal government is headed into a shutdown. What does it mean, who's hit and what's next?
New AI Stock Payouts (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Auto workers still have room to expand their strike against car makers. But they also face risks
New AI Stock Payouts (Ad)
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
NASDAQ:NTRA

Natera (NTRA) Stock Forecast, Price & News

$45.82
-1.47 (-3.11%)
(As of 09/22/2023 ET)
Compare
Today's Range
$45.74
$47.60
50-Day Range
$43.40
$62.52
52-Week Range
$34.00
$63.00
Volume
1.04 million shs
Average Volume
1.17 million shs
Market Capitalization
$5.25 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$70.22

Natera MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
53.3% Upside
$70.22 Price Target
Short Interest
Bearish
5.85% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.24mentions of Natera in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$1.96 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.03) to ($2.64) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

Medical Sector

452nd out of 968 stocks

Medical Laboratories Industry

13th out of 24 stocks


NTRA stock logo

About Natera (NASDAQ:NTRA) Stock

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company's products also comprise Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

NTRA Price History

NTRA Stock News Headlines

Natera Announces Senior Leadership Appointments
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk
I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.
Natera Prices Follow-On Offering At $55/share, Totaling $250 Mln
Natera Inc.
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk
I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.
Natera (NASDAQ: NTRA)
Natera: Strong Growth Amidst Profitability Challenges
The Latest Analyst Ratings for Natera
Natera Reports Second Quarter 2023 Financial Results
Natera Earnings Preview
BTIG Sticks to Its Buy Rating for Natera (NTRA)
What 7 Analyst Ratings Have To Say About Natera
See More Headlines
Receive NTRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter.

NTRA Company Calendar

Last Earnings
8/03/2023
Today
9/23/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NTRA
Fax
N/A
Employees
3,018
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$70.22
High Stock Price Forecast
$80.00
Low Stock Price Forecast
$60.00
Forecasted Upside/Downside
+53.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-547,800,000.00
Pretax Margin
-54.92%

Debt

Sales & Book Value

Annual Sales
$820.22 million
Book Value
$7.23 per share

Miscellaneous

Free Float
103,806,000
Market Cap
$5.25 billion
Optionable
Optionable
Beta
1.11
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Matthew Rabinowitz Ph.D. (Age 50)
    Co-Founder & Exec. Chairman
    Comp: $441.58k
  • Mr. Steven Leonard ChapmanMr. Steven Leonard Chapman (Age 44)
    CEO, Pres & Director
    Comp: $1.15M
  • Mr. Michael B. Brophy M.B.A. (Age 43)
    Chief Financial Officer
    Comp: $611.35k
  • Mr. Daniel Rabinowitz L.L.M.Mr. Daniel Rabinowitz L.L.M. (Age 54)
    LL.M., Sec. & Chief Legal Officer
    Comp: $566.03k
  • Mr. Jonathan Sheena M.Eng.Mr. Jonathan Sheena M.Eng. (Age 50)
    Co-Founder & Director
  • Ms. Olesya A. Anisimova CPA
    Chief Accounting Officer
  • Mr. Rishi Kacker
    Chief Technology Officer
  • Mr. Eric A. Evans
    Chief Scientific Officer
  • Mr. Jerry Diffley
    Chief Compliance & Privacy Officer
  • Mr. Phil Grinnell
    VP of Sales













NTRA Stock - Frequently Asked Questions

Should I buy or sell Natera stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natera in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NTRA shares.
View NTRA analyst ratings
or view top-rated stocks.

What is Natera's stock price forecast for 2023?

6 brokers have issued 1-year target prices for Natera's stock. Their NTRA share price forecasts range from $60.00 to $80.00. On average, they expect the company's share price to reach $70.22 in the next twelve months. This suggests a possible upside of 53.3% from the stock's current price.
View analysts price targets for NTRA
or view top-rated stocks among Wall Street analysts.

How have NTRA shares performed in 2023?

Natera's stock was trading at $40.17 on January 1st, 2023. Since then, NTRA stock has increased by 14.1% and is now trading at $45.82.
View the best growth stocks for 2023 here
.

When is Natera's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our NTRA earnings forecast
.

How were Natera's earnings last quarter?

Natera, Inc. (NASDAQ:NTRA) announced its quarterly earnings data on Thursday, August, 3rd. The medical research company reported ($0.97) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.09) by $0.12. The medical research company earned $261.40 million during the quarter, compared to the consensus estimate of $241.67 million. Natera had a negative net margin of 54.97% and a negative trailing twelve-month return on equity of 88.47%. The business's revenue was up 31.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.50) EPS.

What guidance has Natera issued on next quarter's earnings?

Natera issued an update on its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.01 billion-$1.03 billion, compared to the consensus revenue estimate of $1.01 billion.

What is Steve Chapman's approval rating as Natera's CEO?

158 employees have rated Natera Chief Executive Officer Steve Chapman on Glassdoor.com. Steve Chapman has an approval rating of 91% among the company's employees. This puts Steve Chapman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Natera own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Transocean (RIG) and Allergan (AGN).

When did Natera IPO?

(NTRA) raised $101 million in an initial public offering (IPO) on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

What is Natera's stock symbol?

Natera trades on the NASDAQ under the ticker symbol "NTRA."

Who are Natera's major shareholders?

Natera's stock is owned by a number of institutional and retail investors. Top institutional investors include State Street Corp (2.71%), Alliancebernstein L.P. (2.68%), Kynam Capital Management LP (2.53%), Geode Capital Management LLC (1.44%), Principal Financial Group Inc. (1.29%) and Marshall Wace LLP (1.23%). Insiders that own company stock include Daniel Rabinowitz, Gail Boxer Marcus, Herm Rosenman, James Healy, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Patrick J Donovan, Robert Alan Schueren, Roelof Botha, Rowan E Chapman, Steven Leonard Chapman, Todd C Cozzens and Todd C Cozzens.
View institutional ownership trends
.

How do I buy shares of Natera?

Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Natera's stock price today?

One share of NTRA stock can currently be purchased for approximately $45.82.

How much money does Natera make?

Natera (NASDAQ:NTRA) has a market capitalization of $5.25 billion and generates $820.22 million in revenue each year. The medical research company earns $-547,800,000.00 in net income (profit) each year or ($4.82) on an earnings per share basis.

How many employees does Natera have?

The company employs 3,018 workers across the globe.

How can I contact Natera?

Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The official website for the company is www.natera.com. The medical research company can be reached via phone at (650) 249-9090 or via email at mbrophy@natera.com.

This page (NASDAQ:NTRA) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -